Loading
A phase 3 trial of Entrectinib and Crizotinib in non-small-cell lung cancer, run by Hoffmann-La Roche, active and no longer recruiting.
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases is a phase 3 interventional study registered as NCT04603807 by Hoffmann-La Roche, with 217 participants enrolled, started 2021-09-30 and due to reach its primary completion in 2026-09-30. Interventions recorded: Entrectinib and Crizotinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Entrectinib, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Crizotinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Flatiron Health (Roche), Non-small-cell lung cancer and the tag pipeline.
Shares Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/